Furthermore, since E6AP inhibits adipogenesis by downregulating C/EBPα via targeting it for ubiquitination and subsequent proteasome mediated degradation; its potential as a target protein in the treatment of obesity and type-2 diabetes may further be explored. Here, UBE3A is linked to obesity disorder.